Home » Stocks » ONCT

Oncternal Therapeutics, Inc. (ONCT)

Stock Price: $5.38 USD 0.08 (1.51%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
After-hours: $5.36 -0.02 (-0.37%) Jun 16, 4:50 PM
Market Cap 263.63M
Revenue (ttm) 3.54M
Net Income (ttm) -18.44M
Shares Out 49.09M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $5.38
Previous Close $5.30
Change ($) 0.08
Change (%) 1.51%
Day's Open 5.34
Day's Range 5.21 - 5.50
Day's Volume 792,562
52-Week Range 1.49 - 10.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 weeks ago - GlobeNewsWire

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

3 weeks ago - GlobeNewsWire

Oncternal Therapeutics Inc (NASDAQ: ONCT) has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating TK216 in relapsed or refractory Ewing sarcoma, or soft-tissue sarcoma. D...

3 weeks ago - Benzinga

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announce...

3 weeks ago - GlobeNewsWire

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announce...

4 weeks ago - GlobeNewsWire

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announce...

4 weeks ago - GlobeNewsWire

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -20.00% and -32.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported...

1 month ago - GlobeNewsWire

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announce...

1 month ago - GlobeNewsWire

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

1 month ago - GlobeNewsWire

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

1 month ago - GlobeNewsWire

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

2 months ago - GlobeNewsWire

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

2 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Oncternal Therapeutics, Inc. (ONCT).

2 months ago - Zacks Investment Research

Oncternal Therapeutics (ONCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ...

2 months ago - Zacks Investment Research

This analyst is excited about the company's prospects.

2 months ago - The Motley Fool

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

Other stocks mentioned: ASYS, AYTU, CDMO, IBKR
2 months ago - Zacks Investment Research

Investors need to pay close attention to Oncternal Therapeutics (ONCT) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

2 months ago - GlobeNewsWire

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 50.00% and 169.15%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provid...

3 months ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

3 months ago - GlobeNewsWire

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ORGO, RDUS, TPTX, USNA
4 months ago - Zacks Investment Research

Oncternal has solid data for cirmtuzumab+ibrutinib in MCL and CLL. It has cash it says is enough for 2 years.

4 months ago - Seeking Alpha

Oncternal has potential winner with cirmtuzumab in mantle cell lymphoma. A potential pediatric review voucher for TK216 in Ewing sarcoma alone is worth $80-150 million.

4 months ago - Seeking Alpha

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

4 months ago - GlobeNewsWire

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

5 months ago - GlobeNewsWire

SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology th...

5 months ago - GlobeNewsWire

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

7 months ago - GlobeNewsWire

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company over...

7 months ago - GlobeNewsWire

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provide...

7 months ago - GlobeNewsWire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. ...

8 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentati...

8 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will...

9 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to de...

9 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has en...

9 months ago - Business Wire

Oncternal Therapeutics' (ONCT) CEO Jim Breitmeyer on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business upda...

10 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will r...

10 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will h...

10 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has en...

10 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the Unite...

11 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated cli...

11 months ago - Business Wire

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET

1 year ago - Seeking Alpha

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2019 Results Conference Call March 16, 2020 4:30 PM ET

1 year ago - Seeking Alpha

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor ty... [Read more...]

Industry
Biotechnology
CEO
James Breitmeyer
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
ONCT
Full Company Profile

Financial Performance

In 2020, ONCT's revenue was $3.38 million, an increase of 39.18% compared to the previous year's $2.43 million. Losses were -$17.23 million, -49.62% less than in 2019.

Financial Statements